Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...

Dr Vachhani went over the prognostic models ... you need a transplant," we're still measuring the survival of patients with myelofibrosis on the order of years. Knowing when the sweet-spot time ...

Dr. Zachery Oestreicher is a co-author. Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2024, and ...

Reference: “Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 ...

"A significant unmet need in myelofibrosis remains ... point improvement in Abs-TSS at week 24 compared to baseline," said Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that, following feedback from the U.S. Food and Drug ...

"There remains a tremendous unmet need in myelofibrosis, as less than half ... eventually stop responding to these treatments," said Dr. Raajit Rampal, Director of the Center for Hematologic ...

About 5%-6% of people with polycythemia vera develop myelofibrosis within the first 10 years of being diagnosed. Your doctor will start with a physical exam, including a check of your spleen.

Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...